Shahraki Toktam, Arabi Amir, Feizi Sepehr
Ophthalmic Research Center, Department of Ophthalmology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ophthalmic Research Center, Department of Ophthalmology, Shahid Beheshti University of Medical Sciences, Tehran, 16666, Iran.
Ther Adv Ophthalmol. 2021 May 31;13:25158414211020152. doi: 10.1177/25158414211020152. eCollection 2021 Jan-Dec.
Pterygium is a relatively common ocular surface disease. The clinical aspects and the treatment options have been studied since many years ago, but many uncertainties still exist. The core pathologic pathway and the role of heredity in the development of pterygium are still attractive fields for the researchers. The role of pterygium in corneal irregularities, in addition to the refractive properties of pterygium removal, has been increasingly recognized through numerous studies. The association between pterygium and ocular surface neoplasia is challenging the traditional beliefs regarding the safe profile of the disease. The need for a comprehensive clinical classification system has encouraged homogenization of trials and prediction of the recurrence rate of the pterygium following surgical removal. Evolving surgical methods have been associated with some complications, whose diagnosis and management are necessary for ophthalmic surgeons. According to the review, the main risk factor of pterygium progression remains to be the ultraviolet exposure. A major part of the clinical evaluation should consist of differentiating between typical and atypical pterygia, where the latter may be associated with the risk of ocular surface neoplasia. The effect of pterygium on astigmatism and the aberrations of the cornea may evoke the need for an early removal with a purpose of reducing secondary refractive error. Among the surgical methods, conjunctival or conjunctival-limbal autografting seems to be the first choice for ophthalmic surgeons because the recurrence rate following the procedure has been reported to be lower, compared with other procedures. The use of adjuvant options is supported in the literature, where intraoperative and postoperative mitomycin C has been the adjuvant treatment of choice. The efficacy and safety of anti-vascular endothelial growth factor agents and cyclosporine have been postulated; however, their exact role in the treatment of the pterygium requires further studies.
翼状胬肉是一种相对常见的眼表疾病。多年来,人们一直在研究其临床特征和治疗方法,但仍存在许多不确定性。翼状胬肉发生发展的核心病理途径以及遗传因素所起的作用,仍是研究人员感兴趣的领域。通过大量研究,翼状胬肉除了在切除术后对屈光的影响外,其在角膜不规则方面所起的作用也越来越受到重视。翼状胬肉与眼表肿瘤的关联,正挑战着人们对该疾病安全性的传统认知。建立一个全面的临床分类系统的需求,促使了相关试验的同质化以及对翼状胬肉手术切除后复发率的预测。不断发展的手术方法引发了一些并发症,眼科医生有必要对这些并发症进行诊断和处理。根据综述,翼状胬肉进展的主要危险因素仍是紫外线暴露。临床评估的一个主要部分应包括区分典型和非典型翼状胬肉,后者可能与眼表肿瘤的风险相关。翼状胬肉对散光和角膜像差的影响,可能促使人们需要早期切除,以减少继发性屈光不正。在各种手术方法中,结膜或结膜-角膜缘自体移植似乎是眼科医生的首选,因为据报道该手术术后复发率低于其他手术。文献支持使用辅助治疗方法,术中及术后使用丝裂霉素C一直是首选的辅助治疗手段。抗血管内皮生长因子药物和环孢素的疗效及安全性已得到推测;然而,它们在翼状胬肉治疗中的确切作用仍需进一步研究。